Cancer nanomedicines: oversold or underappreciated?

van der Meel, Roy; Lammers, Twan; Hennink, Wim E.

doi:https://doi.org/10.1080/17425247.2017.1262346

Cancer nanomedicines: oversold or underappreciated?

DSpace/Manakin Repository

Cancer nanomedicines: oversold or underappreciated?

van der Meel, Roy; Lammers, Twan; Hennink, Wim E.

(2017) Expert Opinion on Drug Delivery, volume 14, issue 1, pp. 1 - 5

(Editorial)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Cancer nanomedicines, Clinical translation, Clinical trials, Combination treatment, Drug delivery, Drug targeting, EPR effect, Triggered release, Pharmaceutical Science, Journal Article

DOI: https://doi.org/10.1080/17425247.2017.1262346

ISSN: 1742-5247

Publisher: Informa Healthcare

Note: Funding Information: R van der Meel is supported by a Veni STW Grant (14385) of the Netherlands Organization for Scientific Research (NWO). T Lammers is supported by the European Research Council [StG-309495, PoC-680882] and by the German Research Foundation [LA 2937/1-2].

(Peer reviewed)